Non-infectious uveitis (NIU) Program in Pharmaceutical Benefits Scheme (PBS) 012-24070415

This document outlines details of PBS-subsidised adalimumab for patients with non-infectious uveitis (NIU).

For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.

Non-infectious uveitis (NIU) quick reference

Restrictions	Authority level and section	PA assessment	Processing system	Prescriber type	Prescriber self serve
Initial PB372 form	Written Electronic S85: adalimumab	No	OPA	Must be treated by, or in consultation with: an ophthalmologist a rheumatologist an immunologist with expertise in uveitis	Yes
Grandfather	Telephone Electronic S85: adalimumab	No	OPA	Must be treated by, or in consultation with: an ophthalmologist a rheumatologist an immunologist with expertise in uveitis	Yes
Continuing: originator	Telephone Electronic S85: adalimumab	No	OPA	Must be treated by, or in consultation with: an ophthalmologist a rheumatologist an immunologist with expertise in uveitis	Yes
Continuing: biosimilars	Streamlined S85: adalimumab	No	N/A	Must be treated by, or in consultation with: an ophthalmologist a rheumatologist an immunologist with expertise in uveitis	N/A
Balance of supply (top-up)	Telephone Electronic S85: adalimumab	No	OPA	Must be treated by, or in consultation with: an ophthalmologist a rheumatologist an immunologist with expertise in uveitis	Yes